Clinical significance of in vitro synergism between antibiotics in gram-negative infections.
about
The pharmaco -, population and evolutionary dynamics of multi-drug therapy: experiments with S. aureus and E. coli and computer simulationsBactericidal versus bacteriostatic antibiotic therapy of experimental pneumococcal meningitis in rabbits.Potential of mezlocillin as empiric single-agent therapy in febrile granulocytopenic cancer patientsCarbenicillin plus cefazolin with or without mecillinam as an early treatment of bacteremia caused by gram-negative organisms: randomized double-blind study.Synergism and antagonism among antimicrobial drugs. A personal perspectiveMonotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever.Principles of combination therapy.Synthesis and spectrum of the neoglycoside ACHN-490Comparative clinical study of tobramycin and gentamicin.Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycinSynergistic activity of carbenicillin and gentamicin in experimental Pseudomonas bacteremia in neutropenic rats.Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for ReComparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E testSynergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model.In vitro synergistic activities of tobramycin and selected beta-lactams against 75 gram-negative clinical isolates.Evaluation of combination chemotherapy in a lightly anesthetized animal model of Pseudomonas pneumoniaEmpirical antibiotic therapy in the febrile neutropenic cancer patient: clinical efficacy and impact of monotherapy.Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients.In vitro studies simultaneously examining effect of oxacillin on uptake of radiolabeled streptomycin and on associated bacterial lethality in Staphylococcus aureusComparative synergistic activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, combined with tobramycin, against Pseudomonas aeruginosa.Comparison of azlocillin, ceftizoxime, cefoxitin, and amikacin alone and in combination against Pseudomonas aeruginosa in a neutropenic-site rabbit modelAntimicrobial Activities of a Plethora of Medicinal Plant Extracts and Hydrolates against Human Pathogens and Their Potential to Reverse Antibiotic Resistance.Combination therapy for treatment of infections with gram-negative bacteria.When more is less: Emergent suppressive interactions in three-drug combinations.Accelerated evolution of resistance in multidrug environments.Liposomal antibiotic formulations for targeting the lungs in the treatment of Pseudomonas aeruginosa.Pulmonary infections in immunocompromised children.Controversies in the management of febrile neutropenic cancer patients.Unpredictable response of Pseudomonas aeruginosa to synergistic antibiotic combinations in vitroInteractions of ceftazidime and tobramycin in patients with normal and impaired renal functionEnhanced activity of combination of tobramycin and piperacillin for eradication of sessile biofilm cells of Pseudomonas aeruginosa.Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection.Multifactorial analysis of effects of interactions among antifungal and antineoplastic drugs on inhibition of Candida albicans growth.Early synergistic interactions between amikacin and six beta-lactam antibiotics against multiply resistant members of the family Enterobacteriaceae.Synergism at clinically attainable concentrations of aminoglycoside and beta-lactam antibiotics.In vitro and in vivo studies of three antibiotic combinations against gram-negative bacteria and Staphylococcus aureus.Dynamic interactions of biofilms of mucoid Pseudomonas aeruginosa with tobramycin and piperacillin.Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia.Synergistic activity of gentamicin with trimethoprim or sulfamethoxazole-trimethoprim against Escherichia coli and Klebsiella pneumoniae.Effect of time and concentration upon interaction between gentamicin, tobramycin, Netilmicin, or amikacin and carbenicillin or ticarcillin.
P2860
Q28485988-9A50156E-7FAF-4281-B6EA-08BBC1E93695Q30449424-88ADDFCF-DE03-48FA-9770-00119F4540A6Q33731809-2F57B7E8-B2E5-4B1D-B57B-832F0705E684Q33733238-75338FDB-DCF3-4122-8249-7F36146E8532Q33823475-F4E6D94D-3266-4F7A-B531-889AC7C4B47EQ33980917-1A03A013-E14A-413F-8CF3-95AA6966A3AFQ34053701-B1ED30F5-BEC4-404D-B168-CED41E16DAC0Q34134992-5DCE3F95-6282-4D48-8F94-D9809C8D05B5Q34897347-EDEA280D-887C-4E4F-912E-993CA7BFDC10Q34928940-C92E6F43-CBC6-4471-90CC-7B868B48A469Q34981359-C4A791A5-3F7D-4423-8726-8A16B570F54BQ35124179-A92E1CBF-9335-4DF4-A8A8-A933689603EAQ35126210-91E77A27-280D-45C1-BAE6-F96C354B0EC0Q35131156-8C4DB6BD-C28D-4A50-AEA1-5EDF88FCF88BQ35139159-C692000B-2C8F-4F58-947B-55846DAA48DBQ35537663-8748124A-A273-4F1E-97E1-5F2F2CD176B3Q35540674-A716CF77-7B9B-4A5A-94EE-1814DD90F010Q35573306-55173E69-BEEA-4342-9BBD-2ECFEAD2465EQ35653705-67D7B1AD-E6F5-4768-8329-FA22F1139F34Q35668893-C92F1F7B-C7F4-43EA-8C18-9ED9F7EED555Q35759586-B8ADFB61-6916-4B6D-A3CB-956247C99C09Q35769877-DC8D6545-B8E4-412A-9C7F-1A6F466F7972Q36156077-812E4B05-6824-4087-9104-CE8509A1F1B9Q36364897-38DCCA47-EA90-49C9-96F6-B20C456C7452Q36893628-FAE811CA-9470-4A4A-92B7-7148690123D8Q38214155-FB4FFF7D-3EA5-468A-8C9F-BE07C3CD3D1BQ38785599-11665681-9483-4E1D-9BDC-CD94BB27CEEDQ39603225-A8160C25-D0D4-46D8-A30F-F1089EEC5DD8Q39604645-31C8EEC0-52DA-4112-AC5C-673280697591Q39816217-B817C08E-AE11-45A3-8CD3-5C4A1CC3352AQ39816719-78B46E35-0435-40FE-B564-1A7586D9E88BQ39819234-AEBF2159-B7A8-42D5-A038-AB0886FAEC4CQ39819239-E1527F31-CB9D-4363-B84C-6B829C81A211Q39833523-F6A39393-CD33-4EFE-81BB-2342C9A04D70Q39849094-FE80E75F-ECE3-492C-B388-A65C5250FB44Q39855851-3B6703D2-4BC1-4046-9E5F-C3529F7AC461Q39874925-6308CA4D-676F-4096-93B5-EB0403EA8853Q40462342-3106F4EB-A58D-4595-894D-3DB6FE9D4504Q40619421-4AD314E4-37B0-4A06-9A2E-379E6992E55AQ40620360-D5EF9FF1-9DB1-46AC-94A6-3733BB50394A
P2860
Clinical significance of in vitro synergism between antibiotics in gram-negative infections.
description
1972 nî lūn-bûn
@nan
1972年の論文
@ja
1972年論文
@yue
1972年論文
@zh-hant
1972年論文
@zh-hk
1972年論文
@zh-mo
1972年論文
@zh-tw
1972年论文
@wuu
1972年论文
@zh
1972年论文
@zh-cn
name
Clinical significance of in vi ...... s in gram-negative infections.
@en
type
label
Clinical significance of in vi ...... s in gram-negative infections.
@en
prefLabel
Clinical significance of in vi ...... s in gram-negative infections.
@en
P2093
P2860
P356
P1476
Clinical significance of in vi ...... s in gram-negative infections.
@en
P2093
P2860
P304
P356
10.1128/AAC.2.6.470
P407
P577
1972-12-01T00:00:00Z